Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/03/20 | $12,000,000 | Seed |
Longevity Fund Refactor Capital Shanda Group | undisclosed |
| 04/22/24 | $40,000,000 | Series A |
Ahren Innovation Capital Cerigo Investments Hevolution IAG LongeVC Modi Ventures R42 Fund Refactor Capital Shanda Group | undisclosed |
